Single-dose antimicrobial prophylaxis at abdominal hysterectomy. Cefamandole vs. cefotaxime.
Two hundred twenty-three women were given a single, 1-g, intravenous dose of cefamandole or cefotaxime at elective abdominal hysterectomy in a multicenter, prospective, randomized, blind clinical trial of efficacy and safety. The demographic, surgical, efficacy and safety variables were statistically similar. Prior to discharge from the hospital, 12 women (5.3%) developed major postoperative pelvic infections that required parenteral antimicrobial therapy; no wound infections occurred. There was no correlation between a depressed antimicrobial development of significant postoperative infection. An expanded spectrum of antibacterial activity and a longer serum half-life did not improve clinical efficacy, and single-dose intravenous cephalosporin prophylaxis before abdominal hysterectomy was associated with a low incidence of pelvic infection.
Hemsell
D L
DL
Department of Obstetrics and Gynecology, University of Texas Health Science Center, Dallas.
Martin
J N
JN
Pastorek
J G
JG
Nobles
B J
BJ
Hemsell
P G
PG
Helman
N
N
Blake
P
P
Lindsey
M K
MK
Nicaud
S K
SK
D000328:Adult; D002435:Cefamandole / Q000008:administration & dosage / Q000627:therapeutic use*; D002439:Cefotaxime / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects*; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011897:Random Allocation; D014946:Wound Infection / Q000517:prevention & control*
D002435:Cefamandole; D002439:Cefotaxime